Australian (ASX) Stock Market Forum

NTI - Neurotech International

Jump to new
System

System

Joined
27 June 2010
Posts
4,147
Reactions
309
Neurotech is a medical device and solutions company incorporated in Australia, which operates through its Malta-based subsidiary, AAT Research.

Neurotech is developing neuro-stimulation and neuro-diagnostic solutions to be delivered via the Mente platform, an innovative platform technology to enable medical practitioners to remotely monitor and play an active role in home-based therapies. Neurotech has commercialised its first product, Mente Autism, which assists with the management of children with Autism Spectrum Disorder (ASD) with additional research and development commenced on a number of separate initiatives relating to tinnitus, anxiety, depression and epilepsy.

It is anticipated that NTI will list on the ASX during October 2016.

http://neurotechinternational.com
 
Boom! NTI announces Outstanding preliminary results from US clinical study and reaches new highs. Currently up 63.64% to 27c, up 10.5c from yesterday's close.

-Preliminary findings demonstrate positive changes in children’s neurological function
-Positive effect of Mente Autism device demonstrated with statistical significance on patients measured to date
-Many of the children with autism scoring in a normal range after the treatment
-Update presented at Cambridge International Conference on Mental Health by independent lead investigator, Professor Frederick Carrick
Click to expand...

Lots of interest in this stock today.
 
Neurotech International has announced this morning that the abstract of its US clinical trial results has been published by Frontiers in Neurology, one of the world's leading and most cited medical journals.

Frontiers in Neurology has advised the company that it has provisionally accepted the clinical trial article, "The Treatment of Autism Spectrum Disorder with Auditory Neurofeedback: A Randomized Placebo Controlled Trial Using the MENTE Autism Device", for publication.

The news saw NTI bounce back to 20c after having reached a low of 10c on 18 June.

big.chart-NTI.gif
 
Another little blip for NTI today accompanied by a 90% jump in the share price.

No news recently so unsurprisingly the company received an ASX Price and Volume Query to which it replied that it "is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in the Company's securities."

It further stated that "the Company has recently undergone a Board renewal and indicated a targeted focus on the best possible outcomes for shareholders, this process is continuing."

Other than that, there is not much to go on to explain today's increase in volume and share price.

big.chart-NTI.gif
 
Neurotech launches pilot virtual clinic for autism patients and their carers

Medical solutions developer Neurotech International (ASX: NTI) has launched a pilot version of a virtual clinic which enables doctors to interact with autism patients and remotely monitor their progress.

The online clinic allows for appointments via video conferencing, and will enable doctors to provide a service to clients in areas where access to a clinic is restricted.

Patients signing up to the Mente website under the Early Adopter program will benefit from substantial discounts on the starter pack ($640 compared to $800) and subscription model.

Early Adopters also receive regular updates on Mente and new services offered.

While there are no contractual obligations, Neurotech said it would encourage users to contribute to ongoing validation projects by providing periodic feedback on the website’s usability and their experience using the product. More...
 
Cannabinoid assessment is part of NTI’s recent option to acquire an exclusive worldwide licence to use proprietary cannabis strains from Dolce Cann Global for medicinal use in treating neurological disorders such as autism, epilepsy and ADHD

- Depending on final results, following ACS Laboratories analysis, NTI plans to commence in-vitro testing (using human derived cell lines) on the key priority strains
- If testing is successful, NTI will commence clinical trials with an Australian university, utilising Dolce cannabis strains and its own proprietary Mente autism neurofeedback device which analyses brain wave activity

that news was in July and Sept ... market didn't move, but has recently kicked higher
1608160347839.png


when confirmation came
DOLCE/NTI leads indicate significant increased potency in repairing brain cells when compared to CBD alone
- These results have been achieved using 1/5th the dose of CBD alone (2ug/ml versus 10ug/ml respectively)
- *DOLCE/NTI leads found to exhibit novel modes of action critical in the treatment and management of Alzheimer’s, Huntington’s Disease, Multiple Sclerosis and other neurological disorders
- DOLCE/NTI leads contains minimal THC (<0.3%) which may result in less onerous regulatory pathway towards commercialisation
- Final In-vitro results expected next month (=soon)
 
Noticed price moving yesterday.
Just an update, didn't realise NTI was doing something pot related?
Thanks Dona.

Screenshot_20210211-003341.png
 
I was intrigued by this stock having received a recommendation from Next Investors. As soon as the publication published NT1 today the sheep followed it raising the stock price astronomical high just to finish at the opening price. Next Investor has the skill to ramp up prices and then to disappear.
 
Thought to share the NTI ramping from Next Investors

The share price shot through the roof only to be collapsed into reality

1695474065597.png


BELOW IS AN EXTRACT FROM NEXT INVESTOR EMAIL (ATTACHED)

Introducing our new Portfolio Addition:
Neurotech International (ASX: NTI)
Disclosure: S3 Consortium Pty Ltd (the Company) and Associated Entities own 8,400,000 NTI shares at the time of publishing this article. The Company has been engaged by NTI to share our commentary on the progress of our Investment in NTI over time.
Today we are adding a new Investment to our Portfolio.
We Invested in this company because it has three major share price catalysts coming in the next 6 to 12 months.
Its backers and management have delivered success for us in the past.
And it has spent the last few years building the groundwork to emulate the strategy of a similar company that delivered a 1,300% price rise over the last three years.
(Note: this success is NOT an indication that today’s company will perform the same way)
We have been following this company for a quite a while now, and with years of preparation now completed and three key catalysts coming, today we are adding them to our Portfolio.
Each catalyst on its own has the potential to deliver a significant re-rate in the company’s share price… if successful.
Our latest Investment is Neurotech International (ASX: NTI).

Neurotech International​

ASX: NTI​

Today we will outline why we have Invested in NTI, and what we are looking out for the company to achieve over the 12 months, and also the potential risks we have identified and accepted in this Investment.
NTI is an early stage biotech focused on developing treatments for rare neurological disorders in children, including:
  • Autism Spectrum Disorder
  • Rett Syndrome
  • PANDAS/PANS
  • Cerebral Palsy
NTI expects to deliver the results of three different clinical trials in the next 6-12 months.
…including one set of trial results potentially in the coming weeks.
In terms of the impact on a share price, biotech clinical trial results are the equivalent of oil & gas drilling results - big catalysts.
The clinical trial process is long, expensive and risky, but the prize is enormous on successful trial results and commercialisation.
An example of a biotech that delivered successful clinical trial results is Neuren Pharmaceuticals, which rose 1,300% over three years (it now has a $1.4BN market cap).
This rise was on the back of a successful phase III trial and commercialisation of a treatment for Rett Syndrome (yes, the same disorder NTI is currently running a trial on).
NTI is currently capped at $55M - we Invested because we think NTI can follow a similar pathway to success as $1.4BN Neuren.
(Assuming of course that NTI can deliver success on one or more of its three trials over the next 6-12 months - this is what will start the share price re-rate.)
NTI has specifically created a strategy to replicate Neuren’s success.
It is targeting several different neurological disorders in children with a key focus on rare disorders that are highly valuable to treat and have fast tracked approvals to market.
NTI has set up the foundation to become the next Neuren… now NTI just needs to deliver the all-important successful trial results, and here is where the risk comes in.
 

Attachments

  • NTI NOTE SEPT 23.pdf
    711.2 KB · Views: 2
I'm impressed by the results of a recent PANS/PANDAS trial and the support of Professor Russell Dale, Director of the Kids' Neuroscience Institute [NSW]. There is a You Tube "My Kid's Not Crazy" which is both a professional discussion on PANS and which presents a number of case studies.
Disclosure: Not yet holding, but watching with interest.
 
The Next Investors again heavily pumping NTI. Last they did, price fell drastically however unlike other stocks
The volume has been interesting in the last three days, with prices slowly creeping up.
Look at the chart (Could chartists please put a few comments on your observation?)
Do hold a small parcel.

1706353358591.png
1706353260581.png

1706353424086.png
1706353487200.png
 
I have tipped NTI again for April.
It was not wrong when NTI finished in March, and today, there is no profit or loss mode. So, I will start the April tip at the same price as of 1 March—strange coincidence.
I am still holding NTI and have a hunch to see if there is something better to place me at 7th from top than top from bottom in April.
1711633172158.png
1711633269192.png
 
Neurotech announced the 54th and final patient has completed their last visit for the Phase II/III NTIASD2 clinical trial for children with Autism Spectrum Disorder (ASD). The trial recruited patients aged 8-17 (inclusive) with Level 2 (requiring substantial support) and Level 3 (requiring very substantial support) autism, who have now completed eight weeks of daily NTI164 treatment (the randomisation period of the trial).

Screenshot_20240411-075139_CommSec.jpg
 
Last edited:
NTI published a quiet one-pager about a $10 M placement fund - no more details.
Was it a donation? Ha. The only options are a high-interest loan or selling equity. Either way, it needs further disclosure.
On the same day the news of issuing unquoted options as a free lunch

https://cdn-api.markitdigital.com/a...e I was young :thumbsdown:. :mad::thumbsdown:
 
Interesting reading on Trading View
www.tradingview.com

Australia's Neurotech International rises on positive results from autism therapy trial

** Shares of Neurotech International ASX:NTI rise as much as 5.4% to A$0.078, their highest level since May 22** Biopharmaceutical developer says positive results achieved from Phase II/III clinical trials of autism patients that have received 12 weeks of NTI164 therapy** NTI164 is a therapeutic dr…
www.tradingview.com www.tradingview.com
 
Two announcements and some pumping from Next Investors today did not yield much excitation .
Normally Next Investors bump by more than 20 %
May be company is to recoup financials in CY 2 of 2024
1720664199341.png


1720663999286.png
 

Attachments

  • 02826479.pdf
    364 KB · Views: 0
  • 02826677.pdf
    1.6 MB · Views: 0
Top